The main objective of the study is to compare overall survival in participants receivingxaluritamig versus investigator's choice (cabazitaxel or second androgenreceptor-directed therapy [ARDT]).
The main objective of the study is to compare overall survival in participants receivingxaluritamig versus investigator's choice (cabazitaxel or second androgenreceptor-directed therapy [ARDT]).
